Credit Suisse Ag Merus N.V. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Merus N.V. stock. As of the latest transaction made, Credit Suisse Ag holds 48,694 shares of MRUS stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,694

Previous 44,990 8.23%

Holding current value

$2.22 Million

Previous $1.24 Million 77.2%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$28.03 - $51.82 $103,823 - $191,941	3,704 Added 8.23%	48,694 $2.19 Million
Q4 2023 Feb 08, 2024	SELL	$20.06 - $28.66 $73,720 - $105,325	-3,675 Reduced 7.55%	44,990 $1.24 Million
Q3 2023 Nov 13, 2023	BUY	$20.13 - $27.29 $199,971 - $271,098	9,934 Added 25.65%	48,665 $1.15 Million
Q2 2023 Aug 11, 2023	BUY	$18.33 - $27.18 $56,328 - $83,524	3,073 Added 8.62%	38,731 $1.02 Million
Q1 2023 May 10, 2023	BUY	$14.25 - $20.5 $67,188 - $96,657	4,715 Added 15.24%	35,658 $656,000
Q4 2022 Feb 13, 2023	BUY	$12.8 - $23.66 $114,252 - $211,189	8,926 Added 40.54%	30,943 $478,000
Q3 2022 Nov 10, 2022	BUY	$18.64 - $28.93 $298 - $462	16 Added 0.07%	22,017 $441,000
Q2 2022 Aug 12, 2022	BUY	$13.98 - $29.25 $43,925 - $91,903	3,142 Added 16.66%	22,001 $497,000
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $111,910 - $146,698	4,746 Added 33.63%	18,859 $500,000
Q4 2021 Feb 14, 2022	SELL	$20.0 - $32.29 $2,960 - $4,778	-148 Reduced 1.04%	14,113 $448,000
Q3 2021 Nov 12, 2021	SELL	$16.48 - $27.23 $510 - $844	-31 Reduced 0.22%	14,261 $314,000
Q2 2021 Aug 16, 2021	SELL	$20.0 - $25.48 $111,360 - $141,872	-5,568 Reduced 28.04%	14,292 $301,000
Q1 2021 May 14, 2021	BUY	$16.14 - $29.11 $149,262 - $269,209	9,248 Added 87.15%	19,860 $415,000
Q4 2020 Feb 12, 2021	BUY	$11.4 - $18.36 $120,976 - $194,836	10,612 New	10,612 $186,000

Others Institutions Holding MRUS

# of Institutions

200

Shares Held

61.9M

Call Options Held

243K

Put Options Held

300K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.09B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account